ESC 365 - Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial

Open Access

Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial

Session: Tailored therapeutics advances in heart failure

Topic: Pharmacotherapy

Speaker: Doctor S. Chatur (Boston, US)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Safia Chatur

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

1 presentation

0 follower

5 more presentations in this session

Daprodustat in patients with heart failure and renal anemia: multicenter, open-label, randomized controlled study

Speaker: Doctor Y. Singh (Tokyo, JP)

Telemonitored standardized titration for heart failure with reduced ejection fraction, an open clinical cohort study.

Speaker: Associate Professor N. Bergh (Gothenburg, SE)

The in-hospital use of SGLT2i in heart failure with ischemic aetiology and recent acute coronary syndrome

Speaker: Doctor A. D'Amato (Rome, IT)

Effect of angiotensin converting enzyme inhibitors versus angiotensin receptor blockers on all-cause mortality in heart failure patients receiving quadruple guideline directed medical therapy

Speaker: Assistant Professor A. Sahin (Sivas, TR)

Phenomapping-derived tool to individualize the effect of sacubitril/valsartan in heart failure with preserved ejection fraction

Speaker: Associate Professor J. Park (Seongnam, KR)

Access the full session

Tailored therapeutics advances in heart failure

Speakers: Doctor S. Chatur, Doctor Y. Singh, Associate Professor N. Bergh, Doctor A. D'Amato, Assistant Professor A. Sahin...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources